Equity Overview
Price & Market Data
Price: $7.92
Daily Change: +$0.114 / 1.44%
Daily Range: $7.44 - $8.01
Market Cap: $423,641,024
Daily Volume: 511,549
Performance Metrics
1 Week: 7.67%
1 Month: 63.60%
3 Months: 88.24%
6 Months: 265.3%
1 Year: 349.4%
YTD: 52.96%
Company Details
Employees: 21
Sector: Health technology
Industry: Pharmaceuticals: major
Country:
Details
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in the development of chimeric antigen receptor cell therapy in light chain Amyloidosis and immune-mediated diseases in the United States and Australia. The company' lead product is NXC-201 for relapsed/refractory AL Amyloidos. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.